$PHCI
Panamera Holdings Corp

2023 Q1 Form 10-Q Financial Statement

#000164033423000211 Filed on February 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022 Q3
Revenue $25.00K $25.00K $25.00K
YoY Change
Cost Of Revenue $25.97K $22.89K $38.21K
YoY Change
Gross Profit -$970.00 $2.107K -$13.21K
YoY Change
Gross Profit Margin -3.88% 8.43% -52.84%
Selling, General & Admin $10.46K $5.500K $4.950K
YoY Change 67.63% 125.41% -92.95%
% of Gross Profit 261.03%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.46K $5.495K -$9.000K
YoY Change 67.72% 125.2% -112.82%
Operating Profit -$11.43K -$3.388K -$4.210K
YoY Change 83.28% 38.85%
Interest Expense $965.00 $833.00 -$600.00
YoY Change 148.07% 1143.28% 100.0%
% of Operating Profit
Other Income/Expense, Net $965.00 $833.00
YoY Change -348.07% 1143.28%
Pretax Income -$12.40K -$4.221K -$4.810K
YoY Change 87.08% 68.37% -93.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.40K -$4.221K -$4.810K
YoY Change 87.08% 68.37% -93.18%
Net Earnings / Revenue -49.58% -16.88% -19.24%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 33.21M shares 33.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.680K $2.970K $3.090K
YoY Change 36700.0% 29600.0% 30800.0%
Cash & Equivalents $3.675K $2.967K $3.087K
Short-Term Investments
Other Short-Term Assets $0.00 $60.00 $60.00
YoY Change
Inventory
Prepaid Expenses $0.00 $55.00 $55.00
Receivables $8.330K $8.330K $8.330K
Other Receivables $0.00 $1.500K $1.100K
Total Short-Term Assets $12.01K $12.85K $12.57K
YoY Change 119980.0% 116745.45% 125620.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.01K $12.85K $12.57K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $12.01K $12.85K $12.57K
YoY Change 119980.0% 116745.45% 125620.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.40K $18.28K $17.03K
YoY Change 47.82% 51.31% 26.05%
Accrued Expenses $8.100K $7.630K $7.710K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $43.95K $37.95K $33.95K
YoY Change 397.17% 592.52% 2008.7%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.44K $63.86K $60.19K
YoY Change 210.39% 263.58% 298.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $74.44K $63.86K $60.19K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $74.44K $63.86K $60.19K
YoY Change 210.39% 263.58% 298.0%
SHAREHOLDERS EQUITY
Retained Earnings -$414.7K -$402.3K -$398.0K
YoY Change 11.13% 9.76% 9.35%
Common Stock $3.921K $3.921K $350.4K
YoY Change 0.0% 0.0% 8837.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $600.00 $600.00
YoY Change
Treasury Stock Shares
Shareholders Equity -$62.43K -$51.00K -$47.61K
YoY Change
Total Liabilities & Shareholders Equity $12.01K $12.85K $12.57K
YoY Change 85671.43% 116745.45% 125620.0%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$12.40K -$4.221K -$4.810K
YoY Change 87.08% 68.37% -93.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.290K -$4.120K -$6.090K
YoY Change 57.91% 6.35% -92.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.000K $4.000K 5.000K
YoY Change 79.1% 3.23% -93.98%
NET CHANGE
Cash From Operating Activities -5.290K -$4.120K -6.090K
Cash From Investing Activities
Cash From Financing Activities 6.000K $4.000K 5.000K
Net Change In Cash 710.0 -$120.00 -1.090K
YoY Change 78065325572095900.0% -12100.0% 626.67%
FREE CASH FLOW
Cash From Operating Activities -$5.290K -$4.120K -$6.090K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12853 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12572 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-47614 usd
CY2022Q4 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
400 usd
CY2021Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
3875 usd
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001620749
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39210000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39210000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39210000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q3 us-gaap Preferred Stock Discount On Shares
PreferredStockDiscountOnShares
50000000 usd
CY2022Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2022Q3 pnht Common Stock Shares Authorized1
CommonStockSharesAuthorized1
550000000 shares
CY2022Q3 pnht Common Stock Par Value
CommonStockParValue
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39210000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39210000 shares
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-10-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
000-55569
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
PANAMERA HOLDINGS CORPORATION
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5707326
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
1218 Webster Street
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77002
CY2022Q4 dei City Area Code
CityAreaCode
713
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
289-6200
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
true
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33210000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Profit Loss
ProfitLoss
4221 usd
CY2021Q4 us-gaap Profit Loss
ProfitLoss
2507 usd
CY2022Q4 pnht Imputed Interest On Related Party Loan
ImputedInterestOnRelatedPartyLoan
833 usd
CY2021Q4 pnht Imputed Interest On Related Party Loan
ImputedInterestOnRelatedPartyLoan
67 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39210000 shares
CY2021Q4 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
5052 usd
CY2022Q4 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
25001 usd
CY2021Q4 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0 usd
CY2022Q4 us-gaap Cost Of Revenue
CostOfRevenue
22894 usd
CY2021Q4 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q4 us-gaap Gross Profit
GrossProfit
2107 usd
CY2021Q4 us-gaap Professional Fees
ProfessionalFees
28 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
443 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2412 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1244 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5495 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
2440 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3388 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2440 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
833 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
67 usd
CY2022Q4 us-gaap Other Expenses
OtherExpenses
833 usd
CY2021Q4 us-gaap Other Expenses
OtherExpenses
67 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-4221 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2507 usd
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-2507 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-4221 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-2507 usd
CY2022Q4 pnht Earnings Per Share Basic And Diluted Common Stock
EarningsPerShareBasicAndDilutedCommonStock
-0.00
CY2021Q4 pnht Earnings Per Share Basic And Diluted Common Stock
EarningsPerShareBasicAndDilutedCommonStock
-0.00
CY2022Q4 pnht Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
39210000 shares
CY2021Q4 pnht Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
39210000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-17552 usd
CY2022Q4 pnht Impact Interest On Related Party Loan
ImpactInterestOnRelatedPartyLoan
833 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-4221 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-51002 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-15112 usd
CY2021Q4 pnht Impact Interest On Related Party Loan
ImpactInterestOnRelatedPartyLoan
67 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1434 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2021Q4 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
CY2022Q4 us-gaap Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
-1500 usd
CY2021Q4 us-gaap Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
0 usd
CY2022Q4 pnht Increasedecreaseinpayroll Liabilities Related Party
IncreasedecreaseinpayrollLiabilitiesRelatedParty
75 usd
CY2021Q4 pnht Increasedecreaseinpayroll Liabilities Related Party
IncreasedecreaseinpayrollLiabilitiesRelatedParty
0 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4120 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3874 usd
CY2022Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3875 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-120 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3087 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2967 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11 usd
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021Q4 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q4 pnht Organization Description Of Business
OrganizationDescriptionOfBusiness
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 –</strong> <strong>ORGANIZATION, DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Panamera Holdings Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. Effective October 21, 2021, the Company changed its name from Panamera Healthcare Corporation to Panamera Holdings Corporation and increased the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock, par value $0.0001 per share. The Company’s fiscal year end is July 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company intended to offer management and consulting services to healthcare organizations but have redirected our efforts now to pursuing business opportunities including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration. To date, the Company’s activities have been limited to its formation and the raising of equity capital and consulting services related to agreement signed on March 1, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Change in Control of Registrant</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 26, 2021, the board of director of the Company approved a security purchase agreement with T. Benjamin Jennings or assignees to sell and issue 21,220,000 shares of the common stock at $201,335 in cash. The issuance of 21,220,000 shares of common stock to T. Benjamin Jennings pursuant to the security purchase agreement representing around 54% of the then issued and outstanding shares of the Company at closing date. The Company received the consideration in full and issued the shares on May 12, 2021.</p>
CY2022Q4 pnht Description Of Increse In Shares
DescriptionOfIncreseInShares
the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2022Q4 pnht Fixed Monthly Payment
FixedMonthlyPayment
8333 usd
CY2022Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
0 usd
CY2022Q3 us-gaap Customer Deposits Current
CustomerDepositsCurrent
1500 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-402261 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
25001 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
37946 usd
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
33946 usd
CY2022Q4 us-gaap Insurance Services Revenue
InsuranceServicesRevenue
833 usd
CY2022Q4 pnht Prepaid Wages Related Party
PrepaidWagesRelatedParty
1498 usd
CY2021 pnht Prepaid Wages Related Party
PrepaidWagesRelatedParty
1098 usd
CY2022Q4 us-gaap Preferred Stock Discount On Shares
PreferredStockDiscountOnShares
50000000 usd
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2022Q4 pnht Common Stock Shares Authorized1
CommonStockSharesAuthorized1
550000000 shares
CY2022Q4 pnht Common Stock Par Value
CommonStockParValue
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39210000 shares
CY2022Q4 us-gaap Revenues
Revenues
25001 usd
CY2022Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
8333 usd

Files In Submission

Name View Source Status
0001640334-23-000211-index-headers.html Edgar Link pending
0001640334-23-000211-index.html Edgar Link pending
0001640334-23-000211.txt Edgar Link pending
0001640334-23-000211-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pnht-20221031.xsd Edgar Link pending
pnht_10q.htm Edgar Link pending
pnht_ex311.htm Edgar Link pending
pnht_ex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pnht-20221031_cal.xml Edgar Link unprocessable
pnht-20221031_def.xml Edgar Link unprocessable
pnht-20221031_lab.xml Edgar Link unprocessable
pnht-20221031_pre.xml Edgar Link unprocessable
pnht_10q_htm.xml Edgar Link completed